{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"}],"units":"Participants"}],"description":"Percentage of participants with Acute or Chronic GVHD following transplant","groups":[{"description":"Allogenic Stem Cell Transplant: Fludarabine + Melphalan + Bortezomib followed by Allogenic Rescue","id":"OG000","title":"A: Allogenic Stem Cell Transplant"}],"paramType":"NUMBER","populationDescription":"Allogenic Stem Cell Transplant patients only. Autologous patients do not suffer from GVHD.","reportingStatus":"POSTED","timeFrame":"End of 2 year, post transplant follow-up","title":"Percentage of Participants With Acute or Chronic Graft-versus-host Disease (GVHD) Following Transplant","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}